Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ)
CNY17.44
+0.29 (+1.69%)
CN SHZ Healthcare Medical - Pharmaceuticals
Address
No. 238 Tianshan Street 50035
Shijiazhuang, HE, CN
Shijiazhuang, HE, CN
CEO
Xiang Jun Wu
Website
yiling.cn
IPO
2011-07-28
ISIN CNE1000015S0
Description
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurological, digestive, immune, and urinary diseases, diabetes mellitus, oncology, sleep-improving, and anti-aging. The company also provides dietary supplements, disinfection products, personal protective equipment, as well as formula granules. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY17.44
+0.29 (+1.69%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
15M
Beta
0.47
Float Shares
723.33M
Free Float %
43.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.76% | +0.87% | -4.42% | -7.21% | -13.12% | -4.98% | +9.74% | -43.78% | -22.09% | +52.44% | +32.19% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
17.44
DCF (Unlevered)
15.97
-8.4%
DCF (Levered)
11.85
-32.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.70
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+20.2% ★ Q1'26: +3.5% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+279.1% ★ Q1'26: +20.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+17.8% ★ Q1'26: +23.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+20.3% ★ Q1'26: +20.0% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+14.0% ★ Q1'26: +18.2% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.01× ★ Q1'26: 0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.18B
est: 3.67B (-13.3%)
|
3.85B
est: 3.70B (+4.0%)
|
4.08B
est: 4.05B (+0.8%)
|
4.81B
est: 4.80B (+0.2%)
|
5.83B
est: 5.37B (+8.5%)
|
8.78B
est: 8.45B (+4.0%)
|
10.12B
est: 10.07B (+0.5%)
|
12.53B
est: 11.92B (+5.2%)
|
10.32B
est: 10.78B (-4.3%)
|
6.51B
est: 8.49B (-23.3%)
|
7.83B
est: 8.11B (-3.5%)
|
8.54B
8.39B – 8.69B
+5.3% YoY
|
9.25B
8.99B – 9.52B
+8.4% YoY
|
10.04B
9.80B – 10.27B
+8.4% YoY
|
| EBITDA |
638.15M
est: 597.43M (+6.8%)
|
837.29M
est: 601.80M (+39.1%)
|
842.93M
est: 658.51M (+28.0%)
|
931.20M
est: 781.17M (+19.2%)
|
910.53M
est: 872.89M (+4.3%)
|
1.69B
est: 1.37B (+23.3%)
|
1.87B
est: 1.64B (+14.3%)
|
3.29B
est: 1.94B (+70.0%)
|
2.15B
est: 1.75B (+22.8%)
|
-236.48M
est: 1.53B (-115.4%)
|
2.22B
est: 1.47B (+51.4%)
|
1.54B
1.52B – 1.57B
+5.3% YoY
|
1.67B
1.62B – 1.72B
+8.4% YoY
|
1.81B
1.77B – 1.86B
+8.4% YoY
|
| EBIT |
493.60M
est: 417.31M (+18.3%)
|
619.13M
est: 420.37M (+47.3%)
|
598.27M
est: 459.98M (+30.1%)
|
678.03M
est: 545.66M (+24.3%)
|
650.84M
est: 609.73M (+6.7%)
|
1.43B
est: 959.68M (+48.6%)
|
1.52B
est: 1.14B (+32.8%)
|
2.85B
est: 1.35B (+110.8%)
|
1.61B
est: 1.22B (+31.7%)
|
-837.02M
est: 1.03B (-180.9%)
|
1.59B
est: 988.25M (+61.2%)
|
1.04B
1.02B – 1.06B
+5.3% YoY
|
1.13B
1.09B – 1.16B
+8.4% YoY
|
1.22B
1.19B – 1.25B
+8.4% YoY
|
| Net Income |
430.49M
est: 507.73M (-15.2%)
|
532.69M
est: 571.31M (-6.8%)
|
540.71M
est: 562.53M (-3.9%)
|
599.22M
est: 628.82M (-4.7%)
|
606.50M
est: 641.17M (-5.4%)
|
1.22B
est: 930.82M (+30.9%)
|
1.34B
est: 1.34B (-0.1%)
|
2.36B
est: 2.14B (+10.4%)
|
1.35B
est: 2.09B (-35.3%)
|
-724.52M
est: -763.13M (+5.1%)
|
1.29B
est: 1.22B (+5.5%)
|
1.51B
1.46B – 1.55B
+23.6% YoY
|
1.75B
1.70B – 1.80B
+16.0% YoY
|
2.03B
1.97B – 2.10B
+16.4% YoY
|
| SGA |
1.48B
est: 1.37B (+8.3%)
|
1.86B
est: 1.38B (+35.3%)
|
1.87B
est: 1.51B (+24.5%)
|
2.11B
est: 1.79B (+18.4%)
|
2.58B
est: 2.00B (+29.3%)
|
3.44B
est: 3.14B (+9.4%)
|
3.93B
est: 3.74B (+5.0%)
|
3.87B
est: 4.43B (-12.6%)
|
3.30B
est: 4.01B (-17.7%)
|
2.93B
est: 2.75B (+6.8%)
|
1.18B
est: 2.63B (-55.2%)
|
2.76B
2.72B – 2.81B
+5.3% YoY
|
2.99B
2.91B – 3.08B
+8.4% YoY
|
3.25B
3.17B – 3.32B
+8.4% YoY
|
| EPS |
0.28
est: 0.30 (-7.9%)
|
0.34
est: 0.34 (-0.6%)
|
0.32
est: 0.34 (-5.0%)
|
0.36
est: 0.38 (-4.4%)
|
0.36
est: 0.38 (-6.2%)
|
0.73
est: 0.56 (+31.0%)
|
0.80
est: 0.81 (-0.6%)
|
1.41
est: 1.28 (+10.1%)
|
0.81
est: 1.25 (-35.3%)
|
-0.43
est: -0.46 (+5.9%)
|
0.77
est: 0.73 (+5.5%)
|
0.90
0.87 – 0.93
+23.6% YoY
|
1.05
1.01 – 1.08
+16.0% YoY
|
1.22
1.18 – 1.25
+16.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.82B
OE per share TTM
1.69
Owner's Yield
10.41%
Maintenance CapEx ratio
0.11%
Maint CapEx / Avg PPE
65.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 38 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.89% | 627.2K | 0.95% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.12% | 43.2K | 0.65% |
| 3 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.04% | 7.1K | 0.65% |
| 4 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.03% | 21.7K | 0.55% |
| 5 | State Street SPDR S&P China ETF GXC | 0.01% | 61.6K | 0.59% |
| 6 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 191.4K | 0.19% |
| 7 | Franklin FTSE China ETF FLCH | 0.01% | 30.2K | 0.19% |
| 8 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 5.2K | 0.15% |
| 9 | Franklin FTSE Asia ex Japan ETF FLAX | 0.00% | 1.6K | 0.19% |
| 10 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 362.5K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
129.6K
Shares Outstanding
1.67B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chen Guang Li | Chief Financial Officer & Director | — | male |
| Gen Wu Liu | Supervisor & Director of the Logistics Department of the Administrative Center | — | male |
| Keyuan Zhang | Deputy General Manager & General Manager of the Marketing | — | male |
| Liqin Cai | Accounting Supervisor | — | female |
| Qiu Lian Zhang | Deputy GM & Non-Independent Director | — | female |
| Rui Wu | Secretary of the Board & Non-Independent Director | — | female |
| Wei Dong Xu | Executive Deputy Director of the Human Resources Center & Director | — | male |
| Wei Wang | Deputy GM & Director of Administrative Center | — | female |
| Xiang Jun Wu | Chairman & GM | — | male |
| Xiaolin Zhou | Deputy GM & Director of the Supply Center | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002603.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
